CL097
- Product Name
- CL097
- CAS No.
- 1026249-18-2
- Chemical Name
- CL097
- Synonyms
- CL097;CL097, 10 mM in DMSO;3H-Imidazo[4,5-c]quinolin-4-amine, 2-(ethoxymethyl)-;CL 097,Immunological,inhibit,Oligonucleotide,Toll-like Receptor (TLR),Peptide,TLR7,Heterocycle,modulators,Inhibitor,Reactive Oxygen Species,TLR8,CL-097
- CBNumber
- CB13310325
- Molecular Formula
- C13H14N4O
- Formula Weight
- 242.28
- MOL File
- 1026249-18-2.mol
CL097 Property
- storage temp.
- Store at -20°C
- solubility
- DMSO : 100 mg/mL (412.75 mM; Need ultrasonic)
- form
- Solid
- color
- White to off-white
N-Bromosuccinimide Price
- Product number
- SML2566
- Product name
- CL097
- Purity
- ≥98% (HPLC)
- Packaging
- 5MG
- Price
- $86
- Updated
- 2025/07/31
- Product number
- SML2566
- Product name
- CL097
- Purity
- ≥98% (HPLC)
- Packaging
- 25MG
- Price
- $284.2
- Updated
- 2025/07/31
CL097 Chemical Properties,Usage,Production
Uses
CL097, a potent TLR7 and TLR8 agonist, induces pro-inflammatory cytokines in macrophages[1]. CL097 induces NADPH oxidase priming, resulting in an increase of the fMLF-stimulated ROS production[2].
Biological Activity
CL097, a potent TLR7/8 agonist, induces pro-inflammatory cytokines in macrophages[1]. CL097 induces NADPH oxidase priming, resulting in an increase of the fMLF-stimulated ROS production[2]. CL097 induces activation of NF-κB at 0.1 μM in TLR7 transfected HEK293 cells and at 4 μM in TLR8-transfected HEK293 cells[1].CL097 induces hyperactivation of the NADPH oxidase by stimulating the phosphorylation of p47phox on selective sites in human neutrophils and suggest that p38 MAPK, ERK1/2, protein kinase C, and Pin1 control this process. CL097 induces the phosphorylation of p47phox on specific sites and enhances fMLF-induced p47phox phosphorylation[2]. CL097 and CD40 agonist stimulation induces efficient diabetogenic Cytotoxic T lymphocyte (CTL) function in NOD mice. CL097 (5 mg/kg, s.c.) alone causes a modest specific lysis of the target peptide (～25%). However, treatment with a combination of CL097 and CD40 agonist (10 mg/kg, i.p.) results in an increase of approximately twofold in the specific lysis of the IGRP-peptide-coated targets compared with CL097 treatment alone[3].
in vivo
CL097 and CD40 agonist stimulation induces efficient diabetogenic Cytotoxic T lymphocyte (CTL) function in NOD mice. CL097 (5 mg/kg, s.c.) alone causes a modest specific lysis of the target peptide (～25%). However, treatment with a combination of CL097 and CD40 agonist (10 mg/kg, i.p.) results in an increase of approximately twofold in the specific lysis of the IGRP-peptide-coated targets compared with CL097 treatment alone[3].
| Animal Model: | Female 8.3 NOD mice (5-6 weeks old)[3] |
| Dosage: | 5 mg/kg |
| Administration: | Injected s.c. |
| Result: | Caused a modest specific lysis of the target peptide (～25%). |
IC 50
TLR7; TLR8
References
[1]. Cindy Patinote, et al. Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes. Eur J Med Chem. 2020 May 1;193:112238. [2]. Karama Makni-Maalej, et al. The TLR7/8 agonist CL097 primes N-formyl-methionyl-leucyl-phenylalanine-stimulated NADPH oxidase activation in human neutrophils: critical role of p47phox phosphorylation and the proline isomerase Pin1. J Immunol. 2012 Nov 1;189(9):4657-65. [3]. A S Lee, et al. Toll-like receptor 7 stimulation promotes autoimmune diabetes in the NOD mouse. Diabetologia. 2011 Jun;54(6):1407-16.
CL097 Preparation Products And Raw materials
Raw materials
Preparation Products
CL097 Suppliers
- Tel
- +1-781-999-5354; +17819995354
- marketing@targetmol.com
- Country
- United States
- ProdList
- 32435
- Advantage
- 58
- Tel
- tp@aladdinsci.com
- Country
- United States
- ProdList
- 52923
- Advantage
- 58
- Tel
- +1-781-999-5354;
- support@targetmol.com
- Country
- United States
- ProdList
- 39035
- Advantage
- 58
- Tel
- 16314854226
- info@bocsci.com
- Country
- United States
- ProdList
- 9923
- Advantage
- 65